Product image of Matever (Levetiracetam) supplied by GNH India

Matever

Active Ingredient:
Levetiracetam
Origin:
EU

Matever (Levetiracetam)

Levetiracetam, the active ingredient in Matever, is an antiepileptic presented as an injection solution for intravenous use. It is employed to control various types of seizures, including partial‑onset, myoclonic, and generalized tonic‑clonic seizures, in adult and pediatric patients as prescribed by a physician. It is approved for use in the European Union and is administered under professional medical supervision.

GNH India supplies Matever as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance.

Manufacturer / TM Owner

Pharmathen S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levetiracetam is used in the management of epilepsy, targeting various seizure types.

  • Partial‑onset seizures: reduces frequency and severity of focal seizures.
  • Myoclonic seizures: controls sudden, brief muscle jerks associated with juvenile myoclonic epilepsy.
  • Generalized tonic‑clonic seizures: helps prevent loss of consciousness and convulsive episodes.

How It Works

  • Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This interaction reduces synaptic excitability, thereby decreasing the propagation of abnormal electrical activity that underlies seizure generation. The precise downstream effects involve inhibition of calcium‑dependent release of excitatory neurotransmitters, contributing to its broad antiepileptic activity. Additionally, levetiracetam does not significantly bind to GABA or glutamate receptors, which distinguishes its safety profile.

Side Effects

Levetiracetam may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Dizziness: sensation of lightheadedness or unsteady balance.
  • Fatigue: feeling unusually tired or weak.
  • Headache: mild to moderate head pain.
  • Nausea: upset stomach with urge to vomit.
  • Irritability: mood changes or increased agitation.
  • Somnolence: excessive sleepiness.

Serious or Rare Side Effects

  • Severe allergic reaction: rash, swelling, or difficulty breathing.
  • Stevens‑Johnson syndrome: serious skin disorder with blistering.
  • Blood dyscrasias: low white blood cells or platelets.
  • Mood disturbances: depression or suicidal thoughts.
  • Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Precautions & Warnings

When using levetiracetam injection, clinicians should observe several precautions to ensure patient safety.

  • Renal impairment: adjust dose or monitor renal function in patients with reduced kidney clearance.
  • Concomitant CNS depressants: use caution as combined effects may increase sedation.
  • Psychiatric history: monitor for mood changes, especially in patients with prior depression or anxiety.
  • Pregnancy: limited data; weigh potential benefits against unknown fetal risks.
  • Pediatric use: dosing must be individualized by a specialist; monitor growth and development.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control.
  • Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely)

  • Valproic acid: may increase risk of CNS side effects such as dizziness.
  • Sedative antihistamines: combined use may enhance drowsiness.
  • Opioids: potential additive CNS depression.
  • Oral contraceptives: levetiracetam may slightly reduce hormonal efficacy; consider alternative contraception.

Frequently Asked Questions

Matever is an intravenous formulation of levetiracetam used to treat epilepsy. It is indicated for the control of partial‑onset seizures, myoclonic seizures, and generalized tonic‑clonic seizures in patients for whom oral therapy may not be feasible or when rapid seizure control is required.

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release and stabilizes neuronal membranes. By reducing synaptic excitability, it limits the spread of abnormal electrical activity that triggers seizures, providing broad antiepileptic effects without significant interaction with GABA or glutamate receptors.

The dosing regimen for Matever is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals adjust the dose to achieve optimal seizure control while monitoring for efficacy and tolerability.

Safety data for levetiracetam in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss individual risk factors with patients and consider alternative therapies when appropriate.

To order Matever, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with older agents such as valproate or carbamazepine, levetiracetam has a distinct mechanism (SV2A binding) and a generally favorable drug‑interaction profile. It does not induce hepatic enzymes, which reduces the likelihood of metabolic interactions, but clinicians still monitor for additive CNS effects when combined with other depressants.

Matever must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Matever is administered by intravenous injection or infusion under the supervision of qualified healthcare personnel. The solution is typically diluted in compatible IV fluids and delivered over a period specified by the prescriber, ensuring aseptic technique and appropriate infusion rates.

Serious adverse events include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, blood dyscrasias (e.g., neutropenia, thrombocytopenia), significant mood disturbances like depression or suicidal thoughts, and hepatic dysfunction. Patients should be monitored closely for any of these signs, and treatment should be discontinued if they occur.

Matever is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for patients with a history of serious psychiatric disorders without close monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levetiracetam

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT